NAb wanes after a few months. Ino-4800 triggers a balanced response which is optimal. There are several protecting components akin to NFL team sport.
Only T cell has long term memory and protection. CEPI scientists said a vaccine having short duration which needs boosting while not boost-able is worthless. I couldn’t agree more.
f you compare 1mg to 2mg; you can see that 1mg has higher nab but less T cell response and the 2mg is opposite. What this tells us is, once your body obtain sufficient CD8+ and memory cd4+ cd8+ and B cells, high nab is not needed. nab were higher in 1mg because T cells is lacking a little, they both balance themselves out
Some back of the envelope math for the SP implications of an approved INO- 4800 vaccine.
Moderna sold 100M vaccines to the DoD for $1.9B - in the near future Inovio will do the same either here or abroad.
Let’s assume that revenue results in earnings of 15% or $285M. Dividing by outstanding shares of 169M we get $1.69 EPS. Multiply that by a very conservative P/E of 15 and you get a SP of a little over $25. Biotech P/Es are all over the map, but I’ve seen 45 as a rule of thumb. That produces a SP of $76. That’s for every 100M vaccines sold - a range of $25-76 SP. A billion doses sold equates to ten times that for a whopping SP in the range of $250-$760.
Do that same exercise for INO’s MERS, Lassa fever, Zika, Ebola and well, you understand why Kim thinks INO will be the Tesla of Biotechs. Hope he keeps building that global consortium of manufacturers!
We can talk about the rest of the pipeline some other time, but for now, think about dmAbs which are a $120B opportunity that grows each year.
